• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
DAI Jiangdong, LI Huipeng, SUN Minjie. Effects of polyethylene glycol length on oral absorption of coumarin 6-loaded nanostructured lipid carrier[J]. Journal of China Pharmaceutical University, 2021, 52(3): 293-300. DOI: 10.11665/j.issn.1000-5048.20210305
Citation: DAI Jiangdong, LI Huipeng, SUN Minjie. Effects of polyethylene glycol length on oral absorption of coumarin 6-loaded nanostructured lipid carrier[J]. Journal of China Pharmaceutical University, 2021, 52(3): 293-300. DOI: 10.11665/j.issn.1000-5048.20210305

Effects of polyethylene glycol length on oral absorption of coumarin 6-loaded nanostructured lipid carrier

Funds: This study was supported by the National Natural Science Foundation of China (No.81872817) and the "Double First-Class" University Project of China Pharmaceutical University (No. CPU2018GY07)
More Information
  • Received Date: July 14, 2020
  • Revised Date: May 25, 2021
  • Polyethylene glycol (PEG) of different lengths were prepared to investigate their effects on oral absorption of nanostructured lipid carrier (NLCs).Three kinds of PEG-modified NLCs with different chain lengths, including polyethylene glycol (100) monostearate (S100), polyethylene glycol (55) monostearate (S55), polyethylene glycol (40) monostearate (S40), were prepared by film dispersion method.Coumarin 6 was chosen as a fluorescent probe to characterize the physicochemical properties of NLCs with different lengths.Meanwhile, the stability of NLCs in simulate buffer, the release behavior, cytotoxicity of NLCs, the uptake kinetics and cellular uptake mechanisms were evaluated. This work demonstrated that the thickness of the hydrated layer increased with the increase of PEG length. Of note, S100-modified NLCs (pNLC-EG100) exhibited higher cellular uptake efficiency compared with other formulations. Thus, S100 was optimized as the best molecular weight for PEG-modified NLCs on oral drug delivery system.
  • [1]
    . Pharmaceutics,2019,11(3):E129.
    [2]
    Date AA,Hanes J,Ensign LM. Nanoparticles for oral delivery:Design,evaluation and state-of-the-art[J]. J Control Release,2016,240:504-526.
    [3]
    Khosa A,Reddi S,Saha RN. Nanostructured lipid carriers for site-specific drug delivery[J]. Biomed Pharmacother,2018,103:598-613.
    [4]
    Garbuzenko OB,Kbah N,Kuzmov A,et al. Inhalation treatment of cystic fibrosis with lumacaftor and ivacaftor co-delivered by nanostructured lipid carriers[J]. J Control Release,2019,296:225-231.
    [5]
    Ensign LM,Cone R,Hanes J. Oral drug delivery with polymeric nanoparticles:the gastrointestinal mucus barriers[J]. Adv Drug Deliv Rev,2012,64(6):557-570.
    [6]
    Takeuchi H,Yamamoto H,Niwa T,et al. Enteral absorption of insulin in rats from mucoadhesive chitosan-coated liposomes[J]. Pharm Res,1996,13(6):896-901.
    [7]
    Alp G,Aydogan N. Lipid-based mucus penetrating nanoparticles and their biophysical interactions with pulmonary mucus layer[J]. Eur J Pharm Biopharm,2020,149:45-57.
    [8]
    Lai SK,Wang YY,Hanes J. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues[J]. Adv Drug Deliv Rev,2009,61(2):158-171.
    [9]
    Huckaby JT,Lai SK. PEGylation for enhancing nanoparticle diffusion in mucus[J]. Adv Drug Deliv Rev,2018,124:125-139.
    [10]
    Tan XY,Zhang Y,Wang Q,et al. Cell-penetrating peptide together with PEG-modified mesostructured silica nanoparticles promotes mucous permeation and oral delivery of therapeutic proteins and peptides[J]. Biomater Sci,2019,7(7):2934-2950.
    [11]
    Li HP,Su ZG,Chen ML,et al. Preparation and characterization of nanostructured lipid carriers with difference in particle size[J]. J China Pharm Univ(中国药科大学学报),2015,46(4):436-443.
    [12]
    Sadzuka Y,Nakade A,Hirama R,et al. Effects of mixed polyethyleneglycol modification on fixed aqueous layer thickness and antitumor activity of doxorubicin containing liposome[J]. Int J Pharm,2002,238(1/2):171-180.
    [13]
    Allard-Vannier E,Hervé-Aubert K,Kaaki K,et al. Folic acid-capped PEGylated magnetic nanoparticles enter cancer cells mostly via clathrin-dependent endocytosis[J]. Biochim Biophys Acta Gen Subj,2017,1861(6):1578-1586.
    [14]
    Wang XY,Wang XY,Qiu LZ,et al. Cytotoxicity and cellular uptake of paclitaxel-loaded carboxymethyl chitosan-Rhein polymeric micelles in MCF-7 cells[J]. J China Pharm Univ(中国药科大学学报),2020,51(1):33-37.
  • Related Articles

    [1]MU Yao, ZHAO Huimin, LIU Haochen, LIU Xiaoquan. Advances in drug development for Alzheimer’s disease[J]. Journal of China Pharmaceutical University, 2024, 55(6): 816-825. DOI: 10.11665/j.issn.1000-5048.2024010202
    [2]LU Xiao, WANG Xingru, QI Xueyong, LIAO Lianming, LIAN Yunfei. Research progress and existing problems in the industrialization of stem cell drugs[J]. Journal of China Pharmaceutical University, 2024, 55(2): 270-280. DOI: 10.11665/j.issn.1000-5048.2023111604
    [3]YU Zehao, ZHANG Leiming, ZHANG Mengna, DAI Zhiqi, PENG Chengbin, ZHENG Siming. Artificial intelligence-based drug development: current progress and future challenges[J]. Journal of China Pharmaceutical University, 2023, 54(3): 282-293. DOI: 10.11665/j.issn.1000-5048.2023041003
    [4]Gao Zhonghao. 新型药物递送系统技术在药物研发中的应用和展望[J]. Journal of China Pharmaceutical University, 2023, 54(1): 1-4. DOI: 10.11665/j.issn.1000-5048.2023030303
    [5]XING Xuyang, WANG Xiaochun, HE Wei. Advances in research on tumor immunotherapy and its drug development[J]. Journal of China Pharmaceutical University, 2021, 52(1): 10-19. DOI: 10.11665/j.issn.1000-5048.20210102
    [6]LIU Jiamin, JIA Xiaoqing, DI Bin. Application of three-dimensional cell model in tumor research[J]. Journal of China Pharmaceutical University, 2020, 51(2): 152-160. DOI: 10.11665/j.issn.1000-5048.20200204
    [7]ZHANG Jing. Analysis on research and development of global cardiovascular drugs in the past 6 years[J]. Journal of China Pharmaceutical University, 2018, 49(6): 760-765. DOI: 10.11665/j.issn.1000-5048.20180619
    [8]CHEN Yingying, LI Ruiyan, CHEN Huan, ZHANG Yubin. Development and application of drugs targeting the innate and adaptive immune system in the colon[J]. Journal of China Pharmaceutical University, 2016, 47(4): 388-396. DOI: 10.11665/j.issn.1000-5048.20160402
    [9]YANG Qian, MA Qiujuan, WANG Xiaojian. Suggestions for secondary innovations and generic development for drugs from the perspective of patent — taking HIV protease inhibitor lopinavir as an example[J]. Journal of China Pharmaceutical University, 2015, 46(4): 499-503. DOI: 10.11665/j.issn.1000-5048.20150419
    [10]ZHAO Hong-ping, JIANG Hong-min, XIANG Bing-ren. Analysis on the hot spot targets and tendency of the global cardiovascular drug development in recent 5 years[J]. Journal of China Pharmaceutical University, 2012, 43(6): 573-576.

Catalog

    Article views (209) PDF downloads (628) Cited by()

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return